Dr Peter Houweling
Dr Peter Houweling
Details
Role
Team Leader / Senior Research Officer
Research area
Genomic Medicine
Group
Muscle Research
Dr Peter Houweling is a Team leader and senior research officer in the Muscle Research group at the Murdoch Children’s Research Institute (MCRI). He completed his PhD at the University of Sydney and post-doctoral appointments at the Children’s Hospital Westmead, before moving the MCRI in 2013.
He has almost 15 years of experience in the laboratory where he is working to understand the impact of genetic variants on skeletal muscle performance in health and disease.
His Team now focuses on using stem cells to model and test new treatments for patients with genetic muscle diseases, including Duchenne muscular dystrophy (DMD), Facioscapulohumeral muscular dystrophy (FSHD) and other congenital muscular dystrophies.
He has almost 15 years of experience in the laboratory where he is working to understand the impact of genetic variants on skeletal muscle performance in health and disease.
His Team now focuses on using stem cells to model and test new treatments for patients with genetic muscle diseases, including Duchenne muscular dystrophy (DMD), Facioscapulohumeral muscular dystrophy (FSHD) and other congenital muscular dystrophies.
Dr Peter Houweling is a Team leader and senior research officer in the Muscle Research group at the Murdoch Children’s Research Institute (MCRI). He completed his PhD at the University of Sydney and post-doctoral appointments at the Children’s...
Dr Peter Houweling is a Team leader and senior research officer in the Muscle Research group at the Murdoch Children’s Research Institute (MCRI). He completed his PhD at the University of Sydney and post-doctoral appointments at the Children’s Hospital Westmead, before moving the MCRI in 2013.
He has almost 15 years of experience in the laboratory where he is working to understand the impact of genetic variants on skeletal muscle performance in health and disease.
His Team now focuses on using stem cells to model and test new treatments for patients with genetic muscle diseases, including Duchenne muscular dystrophy (DMD), Facioscapulohumeral muscular dystrophy (FSHD) and other congenital muscular dystrophies.
He has almost 15 years of experience in the laboratory where he is working to understand the impact of genetic variants on skeletal muscle performance in health and disease.
His Team now focuses on using stem cells to model and test new treatments for patients with genetic muscle diseases, including Duchenne muscular dystrophy (DMD), Facioscapulohumeral muscular dystrophy (FSHD) and other congenital muscular dystrophies.
Top Publications
- Houweling, PJ, Crossman, V, Tiong, CF, Coles, CA, Taylor, RL, Clayton, JS, Graham, A, Vlahos, K, Howden, SE, North, KN. Generation of a human ACTA1-tdTomato reporter iPSC line using CRISPR/Cas9 editing. Stem Cell Research 75: 103313 2024 view publication
- Hogarth, MW, Houweling, PJ, Thomas, KC, Gordish-Dressman, H, Bello, L, Pegoraro, E, Hoffman, EP, Head, SI, North, KN. Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy. Nature Communications 8(1) : 14143 2024 view publication
- Rankinen, T, Fuku, N, Wolfarth, B, Wang, G, Sarzynski, MA, Alexeev, DG, Ahmetov, II, Boulay, MR, Cieszczyk, P, Eynon, N, et al. No Evidence of a Common DNA Variant Profile Specific to World Class Endurance Athletes. PLOS ONE 11(1) : e0147330 2024 view publication
- Head, SI, Chan, S, Houweling, PJ, Quinlan, KGR, Murphy, R, Wagner, S, Friedrich, O, North, KN. Altered Ca2+ Kinetics Associated with α-Actinin-3 Deficiency May Explain Positive Selection for ACTN3 Null Allele in Human Evolution. PLOS Genetics 11(2) : e1004862 2024 view publication
- Thomas, KC, Zheng, XF, Suarez, FG, Raftery, JM, Quinlan, KGR, Yang, N, North, KN, Houweling, PJ. Evidence Based Selection of Commonly Used RT-qPCR Reference Genes for the Analysis of Mouse Skeletal Muscle. PLOS ONE 9(2) : e88653 2024 view publication
Page 1 of 14
Share //
